CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- 4 Grant or award Chief Medical Officer acquired 4,500 shares (grant or award)
- 4 Grant or award Senior Vice President, R&D acquired 4,500 shares (grant or award)
- 4 Grant or award Chief Commercial Officer acquired 4,500 shares (grant or award)
- 4 Grant or award SVP, GC & Corporate Secretary acquired 4,500 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 4,500 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 17,500 shares (grant or award)
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market sale Chief Commercial Officer sold 1,126 shares at an average $29.83 ($33,589)
- 4 Open-market sale Chief Medical Officer sold 1,813 shares at $28.91 ($52,414)
- 4 Open-market sale Senior Vice President, R&D sold 3,625 shares at $28.91 ($104,799)
- 4 Open-market sale SVP, GC & Corporate Secretary sold 3,175 shares at $28.91 ($91,789)
- 4 Open-market sale Chief Financial Officer sold 3,625 shares at $28.91 ($104,799)
- 4 Open-market sale Chief Executive Officer sold 2,406 shares at $28.91 ($69,557)
- 4 Open-market sale Chief Medical Officer sold 1,813 shares at $30.75 ($55,750)
- 4 Open-market sale Senior Vice President, R&D sold 3,625 shares at $30.75 ($111,469)
- 4 Open-market sale SVP, GC & Corporate Secretary sold 3,175 shares at $30.75 ($97,631)
- 4 Open-market sale Chief Executive Officer sold 8,734 shares at an average $29.91 ($261,267)
- 4 Open-market sale Chief Financial Officer sold 3,625 shares at $30.75 ($111,469)
- 4 Open-market sale Director sold 25,000 shares at $30.75 ($768,750)
- 8-K Event Other events
Page 32 of 65 · 1,286 filings